Floatz logo

Tak-228

B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1

National Cancer Institute (NCI)Phase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
81/ 100

Competitive context

27 Active assets in the B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 cohort.

Asset / SponsorPhaseRating
METHOTREXATE
OHSU Knight Cancer Institute
Phase 2B
PREDNISONE TABLETS
University of Washington
Phase 2B
Blinatumomab
OHSU Knight Cancer Institute
Phase 2B
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
University of Washington
Phase 2B
MERCAPTOPURINE ANHYDROUS
National Cancer Institute (NCI)
Phase 2B

View all 29 →

Same molecule, other indications

Tak-228 is also rated in:

non-small cell lung carcinomaDormant
BB
Indicative ·
65 / 100
View asset →
Recurrent Lung Non-Small Cell CarcinomaDormant
BB
Indicative ·
65 / 100
View asset →
pancreatic neuroendocrine tumorDormant
B
Indicative ·
61 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →